Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Complex Phytoadaptogens (CFA) is a botanical combination therapy developed by the Vladikavkaz Scientific Center of the Russian Academy of Sciences. It consists of 70% alcohol extracts of *Glycyrrhiza glabra* (Licorice), *Rhodiola rosea* (Golden Root), and *Eleutherococcus senticosus* (Siberian Ginseng) in a 2:1:1 ratio. The therapy is investigated as an adjunct to non-surgical periodontal treatment (NSPT) for patients with chronic periodontitis. CFA functions as an adaptogen, enhancing the body's non-specific resistance to stressors and modulating the immune-inflammatory response. A key feature of its clinical application is chronotherapy, where the timing and dosage of the oral drops are adjusted based on the patient's individual chronotype (morning, independent, or evening) to maximize therapeutic efficacy during disease exacerbations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Complex Phytoadaptogens (CFA).